Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX
Author:
Affiliation:
1. The University of Arizona Cancer Center, Phoenix, AZ, USA
2. Truven Health Analytics, an IBM company, Ann Arbor, MI, USA
3. Celgene Corporation, Summit, NJ, USA
Funder
Celgene
Publisher
Informa UK Limited
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/17512433.2017.1365598
Reference15 articles.
1. Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review. Bethesda (MD): National Cancer Institute; 2015. p. 1975–2012.
2. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
3. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
4. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
5. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Characterization of Chemoresistance in Pancreatic Cancer: A Look at MDR-1 Polymorphisms and Expression in Cancer Cells and Patients;International Journal of Molecular Sciences;2024-08-04
2. SIRT7 knockdown promotes gemcitabine sensitivity of pancreatic cancer cell via upregulation of GLUT3 expression;Cancer Letters;2024-08
3. CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer;Cancer Letters;2024-05
4. Machine Learning Developed a MYC Expression Feature-Based Signature for Predicting Prognosis and Chemoresistance in Pancreatic Adenocarcinoma;Biochemical Genetics;2024-01-21
5. Innovative strategies for effective paclitaxel delivery: Recent developments and prospects;Journal of Oncology Pharmacy Practice;2024-01-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3